Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amedisys Inc (NQ: AMED )

91.36 +0.12 (+0.13%)
Streaming Delayed Price Updated: 3:47 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amedisys Inc

< Previous 1 2 3 4 Next >
Analyst Ratings for Amedisys
Via Benzinga
Meta Platforms To Rally 34%? Here Are 10 Other Analyst Forecasts For Thursday
Via Benzinga
Mastercard To $428? Plus This Analyst Slashes PT On Intel
Barclays cut the price target on Mastercard Incorporated (NYSE: MA) from $430 to $428. Barclays analyst Ramsey El-Assal maintained an Overweight rating on the stock. Mastercard shares fell 0.6% to... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 27, 2022
Upgrades 
Via Benzinga
Expert Ratings for Amedisys
Amedisys (NASDAQ:AMED) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Where Amedisys Stands With Analysts
Analysts have provided the following ratings for Amedisys (NASDAQ:AMED) within the last quarter: 
Via Benzinga
6 Analysts Have This to Say About Amedisys
Amedisys (NASDAQ:AMED) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Why Meta Platforms Shares Dipped Around 25%; Here Are 77 Biggest Movers From Yesterday
Gainers UserTesting, Inc. (NYSE: USER) shares jumped 91.7% to close at $7.40 after the company announced it will be acquired by Thoma Bravo and Sunstone Partners for $1.3 billion. The company also... 
Via Benzinga
Expert Ratings for Amedisys
Within the last quarter, Amedisys (NASDAQ:AMED) has observed the following analyst ratings: 
Via Benzinga
Analyst Ratings for Amedisys
Analysts have provided the following ratings for Amedisys (NASDAQ:AMED) within the last quarter: 
Via Benzinga
7 Analysts Have This to Say About Amedisys
Analysts have provided the following ratings for Amedisys (NASDAQ:AMED) within the last quarter: 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 111 stocks hit new 52-week lows. 
Via Benzinga
Why UserTesting Shares Are Trading Higher By Around 93%? Here Are 53 Stocks Moving In Thursday's Mid-Day Session
Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) gained 111% to $2.03 after the company announced it entered into a license agreement with Transcosmos Digital Technology for its Apromore process... 
Via Benzinga
Credit Suisse, Meta Platforms, Wolfspeed And Some Other Big Stocks Moving Lower On Thursday
U.S. stocks traded mixed, with the Dow Jones gaining more than 300 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Amedisys's Return on Invested Capital Overview
Pulled from Benzinga Pro data, Amedisys (NASDAQ:AMED) showed a loss in earnings since Q2, totaling $25.40 million. Sales, on the other hand, increased by 0.02% to $557.99 million during Q3. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Clearside Biomedical (NASDAQ:CLSD) stock rose 27.3% to $1.35 during Thursday's pre-market session. The market value of their outstanding shares is at $81.2 million. 
Via Benzinga
Amedisys: Q3 Earnings Insights
Amedisys (NASDAQ:AMED) reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Amedisys missed estimated... 
Via Benzinga
Preview: Amedisys's Earnings
Amedisys (NASDAQ:AMED) is set to give its latest quarterly earnings report on Wednesday, 2022-10-26. Here's what investors need to know before the announcement. Analysts estimate that Amedisys will... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022
Upgrades 
Via Benzinga
What 9 Analyst Ratings Have To Say About Amedisys
Over the past 3 months, 9 analysts have published their opinion on Amedisys (NASDAQ:AMED) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Recap: Amedisys Q2 Earnings
Amedisys (NASDAQ:AMED) reported its Q2 earnings results on Wednesday, July 27, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Amedisys beat estimated earnings by... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2022
Upgrades 
Via Benzinga
67 Biggest Movers From Yesterday
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital. 
Via Benzinga
Stephens & Co. Maintains Equal-Weight Rating for Amedisys: Here's What You Need To Know
Stephens & Co. has decided to maintain its Equal-Weight rating of Amedisys (NASDAQ:AMED) and lower its price target from $155.00 to $125.00. Shares of Amedisys are trading down 12.59% over the last 24... 
Via Benzinga
45 Stocks Moving In Tuesday's Mid-Day Session
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.8% to $10.31 as the company agreed to be taken private by TPG Capital,. 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Goldman Sachs cut SunPower Corporation. (NASDAQ: SPWR) price target from $19 to $13. SunPower shares fell 3.1% to $17.37 in pre-market trading. 
Via Benzinga
Analyst Ratings for Amedisys
Over the past 3 months, 5 analysts have published their opinion on Amedisys (NASDAQ:AMED) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,... 
Via Benzinga
Where Amedisys Stands With Analysts
Analysts have provided the following ratings for Amedisys (NASDAQ:AMED) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 25, 2022
Upgrades According to 86 Research, the prior rating for NetEase Inc (NASDAQ:NTES) was changed from Hold to Buy. For the fourth quarter, NetEase had an EPS of $1.56,... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.